Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rF1
- Development stage
- Unknown
- Lead developer
- DynPort Vaccine Company
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
rF1 is a recombinant antigen protein developed as a component of a vaccine against plague, caused by the bacterium Yersinia pestis. It is designed to induce an immune response, specifically targeting the F1 antigen of Y. pestis, to provide protection against both bubonic and pneumonic forms of the disease, particularly relevant for potential exposure via the inhalation route.
- Other names
- recombinant F1 antigenrecombinant plague vaccine antigen
02
Targets
F1 antigen (F1 capsular antigen)
Beyond the preview
Go deeper on rF1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rF1.